AxoGen, Inc.
AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosā¦ read more
Healthcare
Medical Devices
39 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$45.73
Price+8.34%
$3.52
1Y
Price
Market Cap
$2.459b
Mid
Price/Earnings 3y Avg5y Avg
120.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-3.1%
EBITDA Margin-2.2%
Net Profit Margin+0.9%
Free Cash Flow Margin-3.1%
EBITDA Margin-2.2%
Net Profit Margin+0.9%
Free Cash Flow MarginRevenue
$251.174m
+11.5%
1y CAGR+16.5%
3y CAGR+16.1%
5y CAGREarnings
-$33.548m
-113.6%
1y CAGR-39.0%
3y CAGR-23.0%
5y CAGREPS
-$0.68
-100.0%
1y CAGR-31.0%
3y CAGR-16.7%
5y CAGRBook Value
$256.257m
$304.863m
Assets$48.606m
Liabilities$20.066m
DebtDebt to Assets
6.6%
-1.4x
Debt to EBITDAFree Cash Flow
$2.526m
+186.1%
1y CAGR-8825.8%
3y CAGR-6608.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company